Clinical Trial Update: Efficacy and Safety Comparison of Short-course Radiotherapy Followed by CapeOX Chemotherapy Plus Toripalimab With or Without Concurrent Surufatinib in Neoadjuvant Therapy for Mid-to-low Localized Rectal Cancer of High-risk Criteria [Phase 2, Phase 3]

View source ↗

Summary

A phase 2/3 clinical trial evaluating neoadjuvant therapy for high-risk mid-to-low localized rectal cancer, comparing short-course radiotherapy followed by Cape…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Cancer

Drugs mentioned

• Eloxatin (oxaliplatin)
• Surufatinib (Surufatinib)
• Toripalimab (Toripalimab)
• Xeloda (capecitabine)

Snippet

Sponsor: The First Hospital of Jilin University | Conditions: Rectal Cancer | Phase 2, Phase 3 | Status: RECRUITING